• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Almenoff June Sherie

    (Last) (First) (Middle)
    C/O AVALO THERAPEUTICS, INC.
    540 GAITHER ROAD, SUITE 400

    (Street)
    ROCKVILLE MD 20850

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Avalo Therapeutics, Inc. [ AVTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/12/2024 P 500 A $12.499(1) 500 I By Meadowlark Management, LLC(2)
    Common Stock 11/13/2024 P 500 A $13 1,000 I By Meadowlark Management, LLC(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed in multiple trades ranging from $12.00 to $12.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected.
    2. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
    /s/ Donald R. Reynolds, by Power of Attorney 11/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    4/9/2026$48.00Outperform
    Wolfe Research
    4/6/2026$52.00Mkt Outperform
    Citizens
    2/2/2026$50.00Buy
    Guggenheim
    12/18/2025$39.00Outperform
    Mizuho
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    9/5/2025Buy
    TD Cowen
    8/15/2025Overweight
    Cantor Fitzgerald
    6/2/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

    WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the "Option"). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is e

    5/22/26 4:01:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

    Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.

    5/13/26 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Pricing of $375 Million Public Offering

    WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of

    5/5/26 11:33:54 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AVTX
    SEC Filings

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lind Kevin Robert

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/4/26 4:10:15 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Truex Samantha

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/4/26 4:10:14 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kaplan Gilla

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/4/26 4:10:13 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    5/15/26 6:41:16 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    5/15/26 4:34:29 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    5/15/26 4:31:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

    SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 12:05:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

    SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/7/24 5:00:07 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

    6/18/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care